linjc16/ctgov huggingface dataset:
Hypomagnesemia and Diabetic Nephropathy

Study Overview
=================
Brief Summary
-----------------
To find if there is a corrolatation between Microalbuminurea and diabetic retinopathy, in daibetic patients

Detailed Description
-----------------
40 Daibetic patients with microalbuminurea will be subjeted to full clinical examination and fundus examination,20 control diabetics with out microalbuminurea will also be included for comparison,patients will be selected from the outpatient clinic 0f fayoum university hospital.

Official Title
-----------------
Hypomagnesemia as a Marker of Diabeteiv Nephropathy

Conditions
-----------------
Diabetic Nephropathies

Intervention / Treatment
-----------------
* Diagnostic Test: serum magnesium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetics on oral treatment,diabetics on insulin Exclusion Criteria: Healthy volunteers,,hypertensive patients with normal blood glucose

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetics with microalbuminuria<br>Diabetics with micro albuminuria will be subjected to full clinical examination. Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio | Diagnostic Test: serum magnesium<br>* assessment of serum magnesium in all patients<br>|
| Diabetics with normal albuminuria<br>Diabetics with micro albuminuria will be subjected to full clinical examination. Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio | Diagnostic Test: serum magnesium<br>* assessment of serum magnesium in all patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease in serum magnesium | statistical significant change in serum magnesium in diabetics with microalbuminuria | One month |
Interest in Evaluating Primary Hemostasis in Patients With Veno-venous Extracorporeal Membrane Oxygenation (ECMO)

Study Overview
=================
Brief Summary
-----------------
The aim of the study is a better understanding of hemorrhagic events causes in patients with ECMO, prevent them and decrease the number of transfusion.

Detailed Description
-----------------
The most frequent complication during ECMO is hemorrhage especially as a curative anticoagulant treatment is necessary. The primary hemostasis is also affected with a von Willebrand disease and thrombopathy, well known but not studied by recent tests.The identification of primary haemostasis deficits with these tools would allow to supply them and decrease the morbi-mortality related to the transfusion.

Official Title
-----------------
Interest in Evaluating Primary Hemostasis in Patients With Veno-venous Extracorporeal Membrane Oxygenation (ECMO)

Conditions
-----------------
Patients With ECMO

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient older than 18 years old Patient with ECMO Patient hospitalized in an intensive care unit at the University Hospital of Rennes Exclusion Criteria: Known history for constitutional pathology of the primary haemostasis Platelets < 100000 / mm3 or hematocrit < 28 % between H+12 and H+24

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate primary hemostasis in patient with ECMO at University Hospital of Rennes |  | Day 5 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Extracorporeal Membrane Oxygenation (ECMO), Primary hemostasis
Women's Mammography Study To Improve Comfort During Mammography

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine in a randomized trial whether it is possible to decrease the discomfort of mammography by using the analgesic ibuprofen, or by using a scripted, supportive text informing patients about mammography.

Detailed Description
-----------------
This study is designed to evaluate two methods of reducing pain and discomfort caused by mammography, one of the barriers to the procedure.

Official Title
-----------------
Women's Mammography Study Attempting to Improve the Comfort During Screening Mammography CTRC#11-45

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: placebo
* Drug: Ibuprofen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have signed the informed consent. Must either be getting her first mammogram or based on prior experience be expecting level 4 or 5 pain Exclusion Criteria: May not have taken ibuprofen or other pain medication within the last 12 hours. Must not have a contraindication for taking ibuprofen e.g: No history of allergic reactions to ibuprofen or aspirin No recent history with the last year of bleeding from GI tract Not pregnant or suspected of being pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Ibuprofen<br>Pfizer 200 mg caplets (Advil) | Drug: Ibuprofen<br> <br> |
| Placebo Comparator: Placebo<br>Lactulose | Drug: placebo<br>* Lactulose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure of Discomfort of Mammography | The primary outcome measure will be the response to questions on a questionnaire. | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mammogram, Ibuprofen, Pain management
A Comparative Study of High and Low Tidal Volume in Preventing Hypoxemia in Patients With Mechanical Ventilation After Cervical Spinal Cord Injury

Study Overview
=================
Brief Summary
-----------------
This study in order to best tidal volume mechanical ventilation in patients with cervical spinal cord injury (sci) as the research point, through higher low volume Settings to find the difference of two groups of patients to prevent the incidence of hypoxemia, to find suitable Settings, tidal volume in patients with lower mechanical ventilation in patients with cervical spinal cord injury (sci) the incidence of pulmonary complications, live less intensive care unit (ICU).

Official Title
-----------------
Peking University Third Hospital

Conditions
-----------------
Cervical Spinal Cord Injury

Intervention / Treatment
-----------------
* Behavioral: High volume group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All critically ill adult patients with cervical spinal cord injury who require mechanical ventilation and informed consent to be admitted to the Department of Critical Care Medicine of Peking University Third Hospital were selected by the subjects or their close relatives to enter the clinical study. Exclusion Criteria: previous chronic obstructive pulmonary disease, diagnosis of acute respiratory distress syndrome at admission, presence of pneumothorax at admission, subjects or close relatives who refused to participate in the study, and non-signed informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| High volume group<br>The tidal volume of the exposed group was 10ml/kg ideal body weight. | |
| Low volume group<br>The tidal volume of the non-exposed group was 6ml/kg ideal body weight | Behavioral: High volume group<br>* Thea High tidal volume of the exposed group was 10ml/kg ideal body weight<br>* Other names: Low volume group;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of hypoxemia | The oxygenation index is less than 300 | during machinical ventilation |
Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1.

Study Overview
=================
Brief Summary
-----------------
The goal of this project is to get more insight into the (neuro)ophthalmological characteristics of children with neurofibromatosis type 1. This way investigators would like to update the current guidelines for follow up and treatment of optic pathway gliomas. Clinical findings will be compared with the results of Optical coherence tomography (OCT) and MRI (magnetic resonance imaging).

Official Title
-----------------
Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1.

Conditions
-----------------
Neurofibromatosis Type 1

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: neurofibromatosis type 1 Exclusion Criteria: no neurofibromatosis type 1

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neurofibromatosis type 1 children<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity |  | childhood (0 to 18y) | 
| Presence of optic pathway glioma |  | childhood (0 to18y) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Optic pathway glioma, Ophthalmological screening
Hypertension in Minorities Database-Workshop and Publication

Study Overview
=================
Brief Summary
-----------------
To develop a comprehensive database publication (databook) utilizing available published and unpublished data on the prevalence of hypertension and its treatment and control in selected minority populations in the United States -- Hispanic, Asian and American Indian.

Detailed Description
-----------------
BACKGROUND: Data on hypertension among minority populations were lacking prior to the workshop and databook publication. Several reasons why the data were lacking include the biological and cultural diversity of America's minorities, their wide dispersal across the country, and the fact that key data such as death certificate information have sometimes not been recorded. DESIGN NARRATIVE: The objective was accomplished in a two-phase approach as follows: Phase l. In June, 1994 a workshop was held in Washington, D.C. on the epidemiology of hypertension in minorities. The workshop, entitled The Epidemiology of Hypertension in Hispanic Americans, Native Americans, and Asian/Pacific Islander Americans included as participants the investigators who had relevant datasets and were willing to participate in the effort. The investigators were requested to use common definitions of hypertension in their workshop presentations when feasible. In addition, in preparation for a databook publication, each study was asked to provide summary data, using common definitions and a common format, on the prevalence of hypertension in the study population. Data presentations and interpretations at the workshop enabled the investigators and consultants to identify further research needs, further feasible data analyses utilizing available data, and special target groups for demonstration research efforts to enhance the potential success of intervention efforts. Phase 2. A database publication (databook) was designed to include a summary of the workshop proceedings with the appropriate data and interpretations along with summary data from the studies presented in a standard, unified format. The databook, entitled Hypertension in Hispanic Americans, American Indians and Alaska Natives, and Asian and Pacific Islander Americans was published in 1996 and presented the prevalence of hypertension and its treatment and control by age, sex, and minority status, along with other information the planning committee considered relevant.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Post-trauma Lumbar Vertebral Body Reconstruction Using Expandable Cages

Study Overview
=================
Brief Summary
-----------------
INTRODUCTION The expandable cage technology is not new, but several questions remain under-studied. Among them, there are the sagittal balance, the subsidence and the adjacent disc degeneration. Moreover, assessment of the correction and kyphosis regardless of the physiological angles can possibly lead to calculation bias. The objective of this study was to assess the extent to which the functional outcomes were correlated to the quality of the reduction, within a homogeneous series of lumbar vertebral body reconstruction with expandable cages for trauma. MATERIAL AND METHODS Twenty-seven patients with a mean follow-up of 3.9 years were retrospectively analyzed. The Oswestry Disability Index (ODI) was the main outcome and its association with other variables was sought. The local kyphosis and the regional traumatic angle using Stagnara's physiological angles were measured. The lumbar lordosis (LL) was compared to the Pelvic Incidence (PI). The subsidence of the cage and the adjacent disc degeneration (using the UCLA grading score) were quantified. Bone quality was assessed through the Hounsfield Unit of the vertebral body.

Official Title
-----------------
Post-trauma Lumbar Vertebral Body Reconstruction Using Expandable Cages: Comprehensive Long-term Follow-up Outcomes

Conditions
-----------------
Disc Degeneration

Intervention / Treatment
-----------------
* Device: corpectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients suffered from a traumatic lumbar fracture requiring a posterior fusion first Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Corpectomy<br>surgical procedure using expandable cage | Device: corpectomy<br>* vertebral corpectomy using expandable cage<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oswestry Disability Index (ODI) | specific lumbar surgery score | 4 years |
A Study of MD-120 in Patients With Depression

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to verify the efficacy and evaluate the safety of 8-week once-daily oral administration of MD-120 in Japanese patients with depression.

Official Title
-----------------
A Placebo-controlled Study of MD-120 in Patients With Depression

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Drug: Desvenlafaxine 100 mg
* Drug: Desvenlafaxine 50 mg
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with diagnosis of Major Depressive Disorder (MDD) based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5). HAM-D 17 total score of ≥20. Exclusion Criteria: Patient who meets DSM-5 criteria of the following disorders for current or past history. Schizophrenia spectrum and other psychotic disorders Bipolar and related disorders Substance use disorders (exclusive of tobacco and caffeine) Patient who had suicidal behavior in Columbia-Suicide Severity Rating Scale (C-SSRS) within 1 year before start of screening phase.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MD-120 100 mg<br> | Drug: Desvenlafaxine 100 mg<br>* once daily dosing for 8 weeks<br>|
| Experimental: MD-120 50 mg<br> | Drug: Desvenlafaxine 50 mg<br>* once daily dosing for 8 weeks<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* once daily dosing for 8 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | Montgomery-Asberg Depression Rating Scale (MADRS) Total Score: Scale ranges from 0 to 60 with a higher score indicating worsening symptoms of depression. | 8 weeks | 
| Number of Participants With Adverse Events (AEs) |  | 10 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in Hamilton Depression Rating Scale-17 (HAM-D17) Total Score | Hamilton Depression Rating Scale-17 (HAM-D17) Total Score: Scale ranges from 0 to 52 with a higher score indicating worsening symptoms of depression. | 8 weeks | 
| Number of Participants With Adverse Drug Reactions (ADRs) |  | 10 weeks | 
| Plasma Concentration of desvenlafaxine |  | Week 2 through week 8 |
A Clinical Trial for CTD-ILD Treatment

Study Overview
=================
Brief Summary
-----------------
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).

Detailed Description
-----------------
The investigators will assess tolerability and safety at scheduled intervals via standard of care physical exam findings, monitoring complete blood count, serum chemistry, and pulmonary function tests, along with patient reports of medication intolerance and change in symptoms of dyspnea.

Official Title
-----------------
Clinical Trial of Oral Medication for CTD-ILD Treatment

Conditions
-----------------
Interstitial Lung Disease, Connective Tissue Disease

Intervention / Treatment
-----------------
* Drug: N-Acetylcysteine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Subject gives voluntary written informed consent to participate in the study. Subject has been diagnosed with a connective tissue disease and associated interstitial lung disease confirmed by computed tomography of the lungs along with symptoms of cough and/or shortness of breath. Males and females age greater than 18 years at time of screening. Females of childbearing potential must be willing to use a reliable form of medically acceptable contraception and have a negative pregnancy test confirmed at baseline before starting NAC as per standard of care. Women who are surgically sterile or have been post-menopausal for at least two years are not considered to be of child-bearing potential. Exclusion: History of severe chronic kidney disease defined as a glomerular filtration rate of less than 30. Hemoglobin concentration less than 70% of the lower limit of the normal range at time of screening. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: N-Acetylcysteine<br>This is an open label trial, all patient will be entered into one treatment arm. | Drug: N-Acetylcysteine<br>* 600mg by mouth, three times daily for 12 months<br>* Other names: acetylcysteine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulmonary Function Tests | Not recorded. Study terminated due to departure of PI. | Every 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Interstitial lung disease, Connective tissue disease, Scleroderma, Rheumatoid arthritis, Sjogren's syndrome, Mixed connective tissue disease, Dermatomyositis, Polymyositis, Systemic lupus erythematosis